DE

459.16

-1.11%↓

CTAS

206.67

-1.07%↓

CPRT

60.86

-0.52%↓

CSX

27.92

+0.11%↑

PAYX

142.28

-0.78%↓

DE

459.16

-1.11%↓

CTAS

206.67

-1.07%↓

CPRT

60.86

-0.52%↓

CSX

27.92

+0.11%↑

PAYX

142.28

-0.78%↓

DE

459.16

-1.11%↓

CTAS

206.67

-1.07%↓

CPRT

60.86

-0.52%↓

CSX

27.92

+0.11%↑

PAYX

142.28

-0.78%↓

DE

459.16

-1.11%↓

CTAS

206.67

-1.07%↓

CPRT

60.86

-0.52%↓

CSX

27.92

+0.11%↑

PAYX

142.28

-0.78%↓

DE

459.16

-1.11%↓

CTAS

206.67

-1.07%↓

CPRT

60.86

-0.52%↓

CSX

27.92

+0.11%↑

PAYX

142.28

-0.78%↓

Search

Enovis Corp

Open

SectorIndustrieƫn

35.06 2.72

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

34.05

Max

35.37

Belangrijke statistieken

By Trading Economics

Inkomsten

-672M

-703M

Verkoop

56M

561M

EPS

0.98

Winstmarge

-125.353

Werknemers

7,367

EBITDA

-602M

-590M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+78.56% upside

Dividenden

By Dow Jones

Volgende Winsten

8 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-782M

1.8B

Vorige openingsprijs

32.34

Vorige sluitingsprijs

35.06

Enovis Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 jan 2025, 23:28 UTC

Belangrijke Marktbewegers

Maplebear Up on S&P MidCap 400 Inclusion

Peer Vergelijking

Prijswijziging

Enovis Corp Prognose

Koersdoel

By TipRanks

78.56% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 62.71Ā USDĀ  78.56%

Hoogste 75Ā USD

Laagste 46Ā USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Enovis Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

7

Buy

1

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Enovis Corp

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.